Compare
Tandem Diabetes Care Inc vs Inspire Medical Systems, Inc. vs Haemonetics Corp vs iRhythm Holdings, Inc.
| Latest fiscal year | Tandem Diabetes Care Inc TNDM | Inspire Medical Systems, Inc. INSP | Haemonetics Corp HAE | iRhythm Holdings, Inc. IRTC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-28 | 2025-12-31 |
| Revenue | $1.01B | $911.98M | $1.33B | $747.14M |
| Revenue growth (YoY) | +7.9% | +13.6% | -2.0% | +26.2% |
| Gross margin | 53.8% | 85.4% | 59.0% | 70.6% |
| Operating margin | -18.5% | 5.6% | 11.7% | -7.7% |
| Net margin | -20.2% | 15.9% | 7.3% | -6.0% |
| Net income | -$204.71M | $145.42M | $97.31M | -$44.55M |
| EPS (Diluted) | -$3.04 | $4.89 | $2.05 | -$1.39 |
| Operating cash flow | -$9.72M | $116.98M | $293.22M | $80.86M |
| Free cash flow | -$29.67M | $78.48M | $260.44M | $34.52M |
| Cash & equivalents | $90.63M | $104.81M | $245.44M | $236.01M |
| Total assets | $881.11M | $907.32M | $2.40B | $1.02B |
| Total liabilities | $725.94M | $126.16M | n/a | $867.30M |
| Shareholders' equity | $155.17M | $781.16M | $796.32M | $152.75M |
| Return on year-end equity | -131.9% | 18.6% | 12.2% | -29.2% |
| Shares outstanding | 68.29M | 28.58M | 45.25M | 32.30M |
Revenue, most recent five fiscal years
| Fiscal year | Tandem Diabetes Care Inc | Inspire Medical Systems, Inc. | Haemonetics Corp | iRhythm Holdings, Inc. |
|---|---|---|---|---|
| Latest | $1.01B Ended 2025-12-31 | $911.98M Ended 2025-12-31 | $1.33B Ended 2026-03-28 | $747.14M Ended 2025-12-31 |
| 1 year earlier | $940.20M Ended 2024-12-31 | $802.80M Ended 2024-12-31 | $1.36B Ended 2025-03-29 | $591.84M Ended 2024-12-31 |
| 2 years earlier | $747.72M Ended 2023-12-31 | $624.80M Ended 2023-12-31 | $1.31B Ended 2024-03-30 | $492.68M Ended 2023-12-31 |
| 3 years earlier | $801.22M Ended 2022-12-31 | $407.86M Ended 2022-12-31 | $1.17B Ended 2023-04-01 | $410.92M Ended 2022-12-31 |
| 4 years earlier | $702.80M Ended 2021-12-31 | $233.39M Ended 2021-12-31 | $993.20M Ended 2022-04-02 | $322.82M Ended 2021-12-31 |